A Study Investigating Drivers of Physician and Patient Satisfaction Towards Treatment
NCT: NCT07504783 ·
Status: ACTIVE NOT RECRUITING ·
Phase: N/A
· Sponsor: Novartis Pharmaceuticals
· Started: 2026-01-22
· Est. Completion: 2026-03-30
Official Summary
The aim of this study is to assess physician and patient satisfaction with ofatumumab using data collected from physicians and their multiple sclerosis (MS) patients in real-world clinical practice across the United Kingdom (UK), France, Germany, Italy, Spain, China, Japan, and Brazil.
Study Design
- Study Type: OBSERVATIONAL
- Enrollment: 261 participants
Primary Outcomes
- Number and Percentage of Patients by Patient-reported Level of Satisfaction With Current MS Treatment (1 Day)
- Number and Percentage of Patients by Patient-reported MS Status With Their Current Medication Compared to Previous Medication (1 Day)
- Number and Percentage of Patients by Physician-reported Patient Response to Current MS Treatment (1 Day)
- Number and Percentage of Patients by Physician-reported Level of Satisfaction With the Patient's Current MS Treatment (1 Day)
- Number and Percentage of Patients Adherent to Current MS Treatment as Reported by the Physician (1 Day)
Secondary Outcomes
- Number and Percentage of Patients by Factors That Influence How the Patient Rates Current Medication Compared to Previous Medication (1 Day)
- Number and Percentage of Patients by Physician-reported Reason for Current MS Treatment Choice (1 Day)
- Number and Percentage of Patients by Physician-reported Top 5 Reasons for Current MS Treatment Choice (1 Day)
- Number and Percentage of Patients by Physician-reported Main Areas of Improvement for the Patient's Current MS Treatment (1 Day)
Trial Locations
- Novartis, Basel, Switzerland
More Multiple Sclerosis Trials
AI-generated analysis for educational purposes only. This is not medical advice. Discuss clinical trial participation with your doctor. Data sourced from ClinicalTrials.gov.